KEYUAN PHARMA(301281)

Search documents
科源制药第二大股东拟减持 2023年上市正拟关联收购
Zhong Guo Jing Ji Wang· 2025-05-26 06:02
| | | | | | 持股 5%以上的股东或前 10 名股东持股情况(不含通过转融通出借股份) | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 报告期 | 报告期 | 持有有 | 持有无 | 质押、标记或冻结情况 | | | 股东名 | 股东性 | 持股比 | | 内增减 | 限售条 | 限售条 | | | | 称 | 质 | | 末持股 | | | | | | | | | து | 数量 | 变动情 | 件的股 | 件的股 | 股份状态 | 数量 | | | | | | 况 | 份数量 | 份数量 | | | | 力诺投 | 境内非 | | | | | | | | | 资控股 | 国有法 | 34. 39% | 37. 240. | 0 | 37.240. | 0 | 质押 | 29, 340, 000 | | 集团有 | | | 000 | | 000. 00 | | | | | 限公司 | 人 | | | | | | | | | 问泽鸿 | 境内自 | 7.76% | 8, 400, 0 | 0 | 0 | ...
5月26日早间重要公告一览
Xi Niu Cai Jing· 2025-05-26 05:40
Group 1 - Northern Long Dragon is planning to acquire the controlling stake of Henan Zhongsheng and raise matching funds, leading to a stock suspension [1] - The company specializes in the research, design, production, and sales of non-metal composite materials for military vehicle equipment [1] - Koyuan Pharmaceutical's major shareholder plans to reduce their stake by up to 3%, amounting to 324.87 million shares [2] Group 2 - Jiaste Technology's shareholder intends to reduce their stake by up to 3%, totaling 1,428.75 million shares [2] - Chengdi Xiangjiang's subsidiary has won a bid for a data center project with China Mobile, valued at 492 million yuan [3] - Zhongchao Holdings' actual controller sold 223 million shares during a period of stock price fluctuation, representing 0.16% of total shares [4] Group 3 - ST Yushun's stock will resume trading after confirming no significant changes in its operational environment [6] - Xing Shuai Er's shareholder plans to reduce their stake by up to 0.37%, equating to 130 million shares [7] - Weiguang Co. intends to reduce its stake by up to 1.32%, totaling 300 million shares [8] Group 4 - Zhongsheng Pharmaceutical's subsidiary has received ethical approval for two Phase III clinical trials for its innovative peptide drug RAY1225 [9][10] - Nongxin Technology's major shareholder plans to reduce their stake by up to 1.35%, amounting to 135 million shares [12] - Mintai Aluminum has signed a strategic cooperation agreement with Penghui Energy for collaboration in battery technology [14] Group 5 - Youyan Powder's controlling shareholder plans to reduce their stake by up to 1%, totaling 103 million shares [16] - Runjian Co. has been shortlisted for a procurement project with China Mobile, valued at 374 million yuan [17] - Bangyan Technology has terminated its plan to issue shares and raise funds for asset acquisition [18] Group 6 - Xianggang Technology's controlling shareholder intends to reduce their stake by up to 3%, equating to 648.42 million shares [19] - Zhongke Shuguang is undergoing a stock suspension due to a planned share swap merger with Haiguang Information [20]
A股医药股震荡调整,海辰药业跌超10%,科源制药跌超8%,拓新药业、多瑞医药、睿智医药、诺泰生物等跟跌。
news flash· 2025-05-26 01:46
Core Viewpoint - The A-share pharmaceutical sector is experiencing significant fluctuations, with notable declines in several companies' stock prices, indicating a broader market adjustment in this industry [1] Company Summary - Haichen Pharmaceutical has seen its stock price drop by over 10% [1] - Key competitors such as Keyuan Pharmaceutical and Tuoxin Pharmaceutical have also faced declines, with drops exceeding 8% [1] - Other companies in the sector, including Duori Pharmaceutical, Ruizhi Pharmaceutical, and Nuotai Biological, are also experiencing downward trends in their stock prices [1]
科源制药: 关于持股5%以上股东股份减持计划的预披露公告
Zheng Quan Zhi Xing· 2025-05-25 08:11
Core Viewpoint - The major shareholder of Shandong Keyuan Pharmaceutical Co., Ltd., Mr. Wen Zehong, plans to reduce his shareholding by up to 3,248,700 shares, which accounts for 3.00% of the company's total share capital, through centralized bidding and block trading methods [1][2]. Group 1: Shareholder Information - Mr. Wen Zehong holds 8,400,000 shares, representing 7.76% of the company's total share capital [1]. - The planned reduction includes a maximum of 1,082,900 shares (1.00% of total share capital) through centralized bidding and up to 2,165,800 shares (2.00% of total share capital) through block trading [1][2]. Group 2: Reduction Plan Details - The reduction will occur within three months after the announcement, starting fifteen trading days from the date of the announcement [1][2]. - The total number of shares to be reduced through centralized bidding and block trading is capped at 3,248,700 shares [1][2]. Group 3: Shareholder Commitments - Mr. Wen made commitments regarding shareholding restrictions prior to the company's initial public offering, including a 36-month lock-up period for shares acquired before the IPO and a 12-month lock-up period for shares issued during the IPO [2][3]. - If Mr. Wen violates these commitments, any proceeds from unauthorized share reductions will belong to the company, and the company has the right to withhold dividends to recover the amounts [3][4].
科源制药(301281) - 关于持股5%以上股东股份减持计划的预披露公告
2025-05-25 07:45
证券代码:301281 证券简称:科源制药 公告编号:2025-040 山东科源制药股份有限公司 关于持股 5%以上股东股份减持计划的预披露公告 公司持股 5%以上股东问泽鸿先生保证向本公司提供的信息内容真实、准确 和完整,没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 特别提示: 山东科源制药股份有限公司(以下简称"公司")股东问泽鸿先生持有公司 股份8,400,000股(占公司总股本的7.76%),计划以集中竞价方式及大宗交易方 式减持公司股份不超过3,248,700股(不超过公司总股本的3.00%)。其中以集中 竞价交易方式减持公司股份不超过1,082,900股(占公司总股本的1.00%),以大 宗交易方式减持公司股份不超过2,165,800股(占公司总股本的2.00%)。问泽鸿 先生本次以集中竞价方式及大宗交易方式减持,将在本减持计划公告之日起十五 个交易日后的三个月内进行。 公司于近日收到股东问泽鸿先生出具的《关于股份减持计划的告知函》,现 将有关情况公告如下: | 股东名称 | 持股数量(股) | 占公司总股本 ...
资源整合重组打造医药大健康平台,科源制药大涨超5%
Xin Lang Cai Jing· 2025-05-19 12:03
Core Viewpoint - Koyuan Pharmaceutical is actively enhancing its market position through strategic acquisitions and international expansion efforts, aiming to build a competitive healthcare platform and increase profitability for shareholders [2][3][4]. Group 1: Stock Performance and Investor Engagement - On May 19, Koyuan Pharmaceutical's stock rose by 5.63%, closing at 32.62 CNY per share, with a trading volume of 5,707,140 shares and a turnover of 184,453,540 CNY, indicating high market activity [1]. - The company participated in an investor reception event organized by the Shandong Securities Regulatory Bureau, discussing its 2024 performance, governance, development strategy, and sustainability with investors [1]. Group 2: Acquisition of Hongjitang - Koyuan Pharmaceutical announced the acquisition of 99.42% of Hongjitang, aiming to integrate high-quality traditional Chinese medicine assets and create a competitive healthcare platform [2]. - The acquisition is expected to enhance the company's net profit attributable to shareholders, thereby maximizing shareholder value [2]. - Hongjitang, established in 1907 and recognized as a "Chinese Time-honored Brand," holds 150 drug licenses and has leading market shares in key products like Ejiao and Angong Niuhuang Wan [2]. Group 3: Global Expansion and Product Development - Koyuan Pharmaceutical focuses on the research, production, and sales of chemical raw materials and formulations, striving to become a leading domestic and internationally competitive pharmaceutical manufacturer [3]. - The company invested 37.63 million CNY in R&D in 2024, accounting for 8.12% of its revenue, with a 24.56% year-on-year increase in R&D personnel [3]. - The product portfolio includes various categories such as antidiabetic, anesthetic, cardiovascular, and psychiatric drugs, with all products certified by national GMP and several international regulatory bodies [3]. Group 4: International Market Development - Koyuan Pharmaceutical showcased its key products and solutions at two major international exhibitions, CPhI Japan and in-cosmetics Global in the Netherlands, to enhance global visibility and foster international collaborations [4]. - The company has made significant strides in its internationalization strategy, establishing a comprehensive marketing network across Europe, the Americas, and Asia-Pacific, and enhancing its core competitiveness and global influence [4].
科源制药(301281) - 301281科源制药投资者关系管理信息20250515
2025-05-16 00:38
Group 1: Company Overview and Objectives - The main purpose of the acquisition of Hongjitang is to integrate high-quality traditional Chinese medicine assets within the group, creating a competitive healthcare platform [1] - The acquisition aims to enrich the company's product portfolio, enhancing its risk resistance and market competitiveness [1] - The company seeks to leverage synergies to improve operational efficiency and profitability [1] Group 2: Share Issuance and Pricing - The share issuance price for acquiring assets is set at 16.73 yuan per share, which complies with regulations stating that the price must not be lower than 80% of the market reference price [2] - The market reference price is based on the average trading price of the company's shares over the 20 trading days prior to the board resolution announcement [2] - The board has approved the issuance price, and related directors will abstain from voting in the upcoming shareholders' meeting [2]
科源制药(301281) - 301281科源制药投资者关系管理信息20250515
2025-05-15 12:58
Group 1: Financial Performance - In 2024, the company achieved a revenue of 463.72 million CNY, a year-on-year increase of 3.60% [5] - The net profit attributable to shareholders was 60.45 million CNY, a decrease of 21.54% compared to the previous year [5] - Gross profit was 211.49 million CNY, with a decline of 2.94% [6] - Sales expenses increased by 21.69%, amounting to 13.75 million CNY [6] - Other income rose significantly by 289.38%, totaling 11.55 million CNY [6] Group 2: R&D Investment - The company invested 37.63 million CNY in R&D in 2024, representing 8.12% of its revenue [4] - R&D personnel increased by 24.56% compared to 2023 due to numerous ongoing projects [8] Group 3: Strategic Acquisitions - The acquisition of 99.42% of Hongjitang is expected to enhance the company's market competitiveness and product portfolio [3] - Hongjitang's integration will allow the company to extend its business into traditional Chinese medicine and health products [3] Group 4: Market Position and Product Development - The company focuses on chemical raw materials and formulations, with key products including Metformin, Glimepiride, and Isosorbide Mononitrate [4] - The company holds 31 raw material drug registration numbers and 43 chemical drug formulation approvals, with all products passing national GMP certification [14] - The global raw material drug market is projected to reach 236.7 billion USD in 2024, with a compound annual growth rate of 6.78% from 2021 to 2026 [13] Group 5: Future Growth Strategies - The company aims to strengthen existing products while rapidly introducing new varieties to create a second growth curve [10] - Plans to expand CDMO business and enhance collaboration with overseas clients are in place [10] - The company will focus on smart manufacturing and technological innovation to improve production efficiency [15]
科源制药(301281) - 关于参加2025年山东辖区上市公司投资者网上集体接待日活动的公告
2025-05-13 08:26
山东科源制药股份有限公司 证券代码:301281 证券简称:科源制药 公告编号:2025-039 关于参加 2025 年山东辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流,山东科源制药股份有限公司(以下简称 "公司")将参加由山东证监局、山东上市公司协会与深圳市全景网络有限公司 联合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动",现将相 关事项公告如下: 本次活动将采用网络远程的方式举行,投资者可登录"全景路演"网站 (http://rs.p5w.net);或关注微信公众号(名称:全景财经);或下载全景 路演APP,参与本次互动交流。活动时间为2025年5月15日(周四)15:00-16:30。 届时公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、 融资计划和可持续发展等投资者关心的问题,与投资者进行沟通与交流,欢迎广 大投资者踊跃参与! 特此公告! 山东科源制药股份有限公司 董事会 2025年5月13日 ...
科源制药: 2024年年度权益分派实施公告
Zheng Quan Zhi Xing· 2025-05-12 11:41
益分派方案一致。 间未超过两个月。 二、本次实施的权益分派方案 本公司2024年年度权益分派方案为:以公司现有总股本108,290,000股为基 数,向全体股东每10股派2.000000元人民币现金(含税;扣税后,通过深股通持 有股份的香港市场投资者、境外机构(含QFII、RQFII)以及持有首发前限售股 的个人和证券投资基金每10股派1.800000元;持有首发后限售股、股权激励限售 股及无限售流通股的个人股息红利税实行差别化税率征收,本公司暂不扣缴个人 所得税,待个人转让股票时,根据其持股期限计算应纳税额【注】;持有首发后 限售股、股权激励限售股及无限售流通股的证券投资基金所涉红利税,对香港投 资者持有基金份额部分按10%征收,对内地投资者持有基金份额部分实行差别化 税率征收), 【注:根据先进先出的原则,以投资者证券账户为单位计算持股期限,持股 三、股权登记日与除权除息日 证券代码:301281 证券简称:科源制药 公告编号:2025-038 山东科源制药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚 假记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司(以下简称"公 ...